ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix tillförs cirka 22 MSEK genom utnyttjandet av teckningsoptioner och beslutar om riktad nyemission

Acarix AB (publ) (“Acarix” eller “Bolaget”) genomförde under december 2022 en företrädesemission av aktier och teckningsoptioner av ser...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix raises approximately SEK 22 million through exercise of warrants and resolves on a directed share issue

In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrants of series 2022:U (the ...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2023

Announcement from Acarix’s annual general meeting

The annual general meeting 2023 ("AGM") of Acarix AB ("Acarix" or the "Company") was held today on 11 May...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2023

Kommuniké från årsstämman i Acarix

Årsstämman 2023 i Acarix AB ("Acarix" eller "Bolaget") hölls idag den 11 maj 2023 i Stockholm varvid aktieägarna fa...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2023

Acarix AB (publ) publishes Interim Report, January – March 2023

2023 is off to a good start In the first quarter of 2023 our strategy delivered important results with a breakthrough order from the la...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 May 2023

Acarix AB (publ) publicerar delårsrapport, januari – mars 2023

2023 har börjat bra Under första kvartalet 2023 levererade vi viktiga delresultat med en genombrottsorder från den största vårdgivaren ...
Continue reading
author-avatar acarix
Press
August 6, 2024
02 May 2023

The exercise period for Acarix warrants of series 2022:U begins today

In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrants of series 2022:U (the ...
Continue reading
author-avatar acarix
Press
August 6, 2024
02 May 2023

Idag inleds nyttjandeperioden för Acarix teckningsoptioner av serie 2022:U

Acarix AB (publ) (“Acarix” eller “Bolaget”) genomförde under december 2022 en företrädesemission av aktier och teckningsoptioner av ser...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Apr 2023

Acarix AB’s Annual Report 2022

Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announces that the Annual Report for 2022 is available as a pdf on...
Continue reading
author-avatar acarix
Press
August 6, 2024
20 Apr 2023

Acarix AB’s Årsredovisning 2022

Acarix, ledare inom akustisk och AI-baserad hjärtdiagnostik, meddelar idag att årsredovisning för 2022 finns tillgänglig som pdf på bol...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Feb 2023

Acarix AB (publ) publicerar Bokslutskommuniké 2022

Strategiskt skifte till fullt kommersiellt fokus på USA-marknaden nu på plats När vi summerar 2022 blir det tydligt att Acarix på kort ...
Continue reading
author-avatar acarix
Press
August 6, 2024
16 Feb 2023

Acarix AB (publ) publishes Year-End Report 2022

Strategic shift towards full commercial focus on the US market now in place As we sum up 2022, it becomes clear that Acarix has in a sh...
Continue reading
  • «
  • ‹
  • 2
  • 3
  • 4
  • 5
  • 6
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
info@acarix.com

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • News
  • Press
  • Events
  • Cookie policy
  • Full Disclaimer
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Full Disclaimer
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
      • What is Coronary Artery Disease
      • Diagnosing CAD
    • About the product
      • The Cadscor System
      • How Does it Work
  • Resources
    • Testimonial
      • HCP Stories
      • Patients Stories
    • References
      • Clinical Studies
      • Downloads (US)
      • Downloads (EU)
    • Support
      • Training
      • Faq
      • Reimbursement
    • Physician Locator
      • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
      • About Acarix
      • Leadership
      • Join The Team
    • Get in touch
      • Contact Us
      • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.